Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Metyrapone/oxazepam - Embera

Next Previous
X
Search
Drug Profile

Metyrapone/oxazepam - Embera

Alternative Names: EMB 001C; EMB-001

Latest Information Update: 25 Jul 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Louisiana State University
  • Developer Embera NeuroTherapeutics
  • Class Antidepressants; Antihormones; Anxiolytics; Behavioural disorder therapies; Benzene derivatives; Benzodiazepinones; Drug withdrawal therapies; Halogenated hydrocarbons; Ketones; Pyridines; Smoking cessation therapies
  • Mechanism of Action GABA A receptor agonists; Glucocorticoid receptor antagonists; Steroid 11-beta-hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Cocaine-related disorders

Highest Development Phases

  • Phase II/III Smoking withdrawal
  • Phase II Cocaine-related disorders
  • Preclinical Eating disorders; Gambling; Post-traumatic stress disorders; Substance-related disorders

Most Recent Events

  • 25 Jul 2024 Metyrapone/oxazepam is still in preclinical trials for Eating disorders in USA (PO) (Embera Neuro Therapeutics pipeline, July 2024)
  • 25 Jul 2024 Metyrapone/oxazepam is still in preclinical trials for Gambling in USA (PO) (Embera Neuro Therapeutics pipeline, July 2024)
  • 25 Jul 2024 Metyrapone/oxazepam is still in preclinical trials for Post-traumatic stress disorders in USA (PO) (Embera Neuro Therapeutics pipeline, July 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top